Can Gabapentin Make Nerve Pain Worse?

Gabapentin does not typically make nerve pain worse through a direct pharmacological action, but several real-world scenarios can make it feel that way. The drug can lose effectiveness over time, cause side effects that mimic worsening pain, build up to toxic levels in people with kidney problems, and trigger rebound pain if stopped abruptly. In at least one animal model, chronic use has even produced genuinely paradoxical effects. So while the short answer is “not usually,” the longer answer depends on dose, duration, individual biology, and how the medication is managed.

How Gabapentin Works on Nerve Pain

Gabapentin was originally developed as an anti-seizure medication, and its pain-relieving properties were discovered somewhat by accident. Despite decades of use, its exact mechanism still is not fully pinned down. The best-understood action involves calcium channels on nerve cells in the spinal cord. Gabapentin binds to a specific part of these channels and reduces the flood of calcium that normally triggers pain signaling.¹ Lab studies on sensory neurons have shown that gabapentin can cut calcium influx by roughly 25 to 30 percent, with the drug preferentially targeting the type of nerve current most involved in pain transmission.²

This mechanism matters for understanding why gabapentin might seem to fail. It dials down pain signals rather than eliminating them. If the underlying nerve damage is progressing, or if the body adapts to the drug’s presence, the partial reduction in signaling may no longer be enough to keep pain at a manageable level. That is not the drug making pain worse so much as the balance tipping.

When Gabapentin Stops Working Over Time

One of the most common reasons people feel their nerve pain is getting worse on gabapentin is that the drug gradually becomes less effective. A rat study on nerve injury found that gabapentin’s ability to reduce pain-related hypersensitivity declined over time, and the researchers traced this to a specific change in the brain. A protein called glutamate transporter-1 in a brainstem region called the locus coeruleus was downregulated during chronic treatment, which weakened the brain’s own pain-suppression pathway that gabapentin relies on.³

This is an animal study, so the findings do not translate directly to humans. But clinicians have long observed that some patients report diminishing relief after months or years on gabapentin, and this research offers a plausible biological explanation. It also suggests the problem is not tolerance in the way people think of it with painkillers. The issue is not that the drug stops binding to its target; rather, the brain’s downstream circuitry changes in a way that undermines the drug’s overall effect. The same study found that adding a second medication (valproate) could rescue gabapentin’s lost efficacy by restoring the transporter protein, hinting that combination strategies might help when gabapentin alone fades.

Genuinely Paradoxical Effects

There is at least one documented situation where continuous gabapentin use appeared to actively make a pain-related condition worse rather than simply failing to help. In a study of rats with complete spinal cord injuries, chronic high-dose gabapentin paradoxically increased the frequency of spontaneous autonomic dysreflexia, a dangerous condition involving sudden spikes in blood pressure triggered by sensory input below the injury. This happened even though single acute doses of gabapentin successfully reduced induced episodes of the same condition.⁴

The researchers concluded that acute and chronic gabapentin work through distinct mechanisms, and the chronic effect can go in the opposite direction from the acute one. This is an important finding even though it comes from animal research and specifically concerns spinal cord injury rather than typical neuropathic pain. It establishes the principle that gabapentin’s effects are not always one-directional. For people with spinal cord injuries on long-term gabapentin, this research raises genuine questions worth discussing with a specialist. For the broader population of nerve pain patients, it serves as a reminder that “more drug for longer” does not always equal “more relief.”

Side Effects That Mimic Worsening Pain

Gabapentin causes several side effects that can easily be confused with the nerve pain itself getting worse. Peripheral edema, a swelling in the legs and feet, is one of the most deceptive. A pooled analysis of three clinical trials in patients with postherpetic neuralgia found that those taking gabapentin at 1,800 mg per day or more had a peripheral edema rate of about 7.5 percent, compared with roughly 1.6 percent for placebo.⁵ This swelling can be uncomfortable and even painful in itself, and if someone already has nerve pain in their legs or feet, the added pressure and inflammation from edema can make the whole situation feel worse.

In one published case, a patient developed severe bilateral pitting edema with a clear dose relationship to gabapentin. The swelling was painful enough to be a significant clinical problem on its own.⁶ Because edema develops gradually and the connection to gabapentin is not always obvious, patients and even clinicians sometimes attribute the increased discomfort to the underlying nerve condition progressing rather than to the drug treating it.

Other common side effects from that same pooled analysis included dizziness (about 20 percent at lower doses) and drowsiness (about 15 percent).⁵ While these are not pain per se, they affect quality of life and can compound the misery of living with chronic nerve pain. Someone who is dizzy and exhausted all the time may perceive their overall condition as worse, even if the nerve pain itself is technically unchanged or improved.

The Absorption Ceiling

Gabapentin has an unusual pharmacological quirk that contributes to the feeling that it stops working at higher doses. The drug relies on a specific transport system in the gut to get absorbed, and that system has a limited capacity. As the dose goes up, absorption does not keep pace. Clinical data show that bioavailability drops from about 74 percent at a 100 mg dose to roughly 36 percent at 1,600 mg.⁷ This pattern has been confirmed across different patient populations, including older adults in nursing home settings.⁸

What this means in practice is that doubling your gabapentin dose does not double the amount of drug that actually reaches your bloodstream. Someone who goes from 900 mg to 1,800 mg per day might expect twice the pain relief, but their body is absorbing a much smaller fraction of each pill. The unabsorbed drug passes through the gut without doing anything useful. This can create a frustrating situation where a doctor keeps raising the dose, the patient sees minimal improvement, and everyone concludes the pain must be getting worse when the real issue is a pharmacokinetic ceiling.

Why Splitting Doses Differently Can Matter

The standard gabapentin regimen is three times a day, but the absorption ceiling described above means that spreading the same total daily dose into more frequent, smaller doses can actually get more drug into the bloodstream. A study comparing four-times-daily dosing with three-times-daily dosing found that patients on the four-dose schedule had significantly lower daily pain scores between day 3 and day 10. They also reported fewer side effects like dizziness, unsteadiness, drowsiness, and nausea during the full 14-day study period.⁹

The same study found that patients on three-times-daily dosing experienced significantly more breakthrough pain episodes during the period when they were emerging from sleep. This is a practical detail that can shape someone’s perception of whether gabapentin is working. If you are consistently waking up in pain because your last dose has worn off, it is easy to conclude the drug is making things worse or not working at all. A dosing schedule adjustment, rather than a dose increase, might be the fix.

Withdrawal and Rebound Pain

Stopping gabapentin abruptly or tapering too quickly can produce a rebound effect where pain temporarily flares beyond its baseline level. This is well-recognized in clinical practice. The nervous system adapts to gabapentin’s dampening effect on calcium channels, and when the drug is suddenly removed, the resulting rebound in neural excitability can make pain feel dramatically worse than it was before treatment started.

This phenomenon creates a tricky perceptual trap. If someone stops gabapentin because they do not think it is helping, and their pain then spikes, they may conclude either that the drug was secretly working all along or that it somehow made the underlying condition worse. In most cases, neither interpretation is quite right. The spike is a temporary withdrawal effect that settles down over days to weeks as the nervous system readjusts. The key practical takeaway is that gabapentin should always be tapered gradually rather than stopped cold, and any assessment of whether the drug is truly helping should be made during a slow, supervised taper rather than after an abrupt stop.

Kidney Function and Toxic Accumulation

Gabapentin is eliminated almost entirely by the kidneys, with no significant liver metabolism. In people whose kidneys are not working well, the drug accumulates in the blood to levels far beyond what is intended. A study comparing patients across different levels of kidney function found that those with severe chronic kidney disease had average gabapentin blood levels more than ten times higher than patients with normal kidney function. Toxicity occurred exclusively in patients with impaired kidneys, and those with the worst kidney function had toxicity rates approaching 78 percent.¹⁰

Gabapentin toxicity does not typically present as increased nerve pain. The symptoms tend to be neurological: confusion, extreme sedation, unsteadiness, jerky movements, and sometimes altered consciousness. But someone experiencing these symptoms alongside their existing nerve pain could reasonably feel that their overall condition is deteriorating. The fix is straightforward: dose reduction based on kidney function. For older adults, this is especially relevant because kidney function declines with age, and a dose that was appropriate five years ago may be too high now even if nothing else has changed.

The Opioid Interaction Problem

Many people with nerve pain take gabapentin alongside opioid medications, and this combination carries specific risks that can complicate the picture. A large population-based study found that people prescribed both gabapentin and opioids had roughly 50 percent higher odds of opioid-related death compared with those on opioids alone, after adjusting for other factors. At moderate and high gabapentin doses, the increased risk was nearly 60 percent.¹¹

This finding does not directly address whether gabapentin makes nerve pain worse, but it matters for the broader question of whether adding gabapentin to a pain regimen always helps. The combination increases sedation and respiratory depression, which means the opioid dose sometimes needs to be reduced when gabapentin is added. If the opioid reduction is not carefully managed, the net effect on pain control could be negative. And the safety risk means that for some patients, the gabapentin-opioid combination creates more problems than it solves, even if gabapentin is technically reducing some of the nerve pain signal.

How Well Gabapentin Actually Works for Nerve Pain

Context for any discussion of gabapentin “making pain worse” requires acknowledging that the drug’s overall track record for nerve pain is real but modest. A Cochrane review covering 29 studies and over 3,500 participants found that about 43 percent of people on gabapentin achieved at least moderate improvement, compared with 26 percent on placebo. For substantial improvement, the numbers were 31 percent versus 17 percent. That translates to needing to treat roughly six people for one to experience meaningful benefit beyond placebo.¹²

Those numbers mean that more than half of people taking gabapentin for nerve pain do not get meaningful relief. They do, however, get side effects: about two-thirds experienced at least one adverse event, one in five had dizziness, one in six had drowsiness, and about one in twelve developed peripheral edema or problems with walking.¹² For a non-responder experiencing side effects but no pain relief, it would be entirely reasonable to feel that gabapentin is making life worse, even if it is not technically increasing the nerve pain signal itself. The distinction between “gabapentin made my nerve pain worse” and “gabapentin gave me new problems without fixing the old one” may feel academic when you are the person living it.

The Cochrane data also showed that the strongest evidence existed for postherpetic neuralgia, painful diabetic neuropathy, and mixed neuropathic pain. For other types of nerve pain, the evidence was thinner. Someone taking gabapentin for a condition where it has weaker evidence of benefit is more likely to end up in the non-responder group and more likely to feel the drug is not helping or is making things worse.

The Role of Expectation

Psychology plays a bigger role in pain medication outcomes than most people realize. The nocebo effect, essentially the evil twin of the placebo effect, means that expecting a drug to cause problems can actually produce those problems. A systematic review of antimigraine drug trials found that patients in placebo groups reported side effects matching the active drug at surprisingly high rates. When the active drug was an anticonvulsant (the same drug class as gabapentin), placebo recipients developed symptoms like appetite loss and memory problems, which are known anticonvulsant side effects.¹³

This does not mean that anyone whose pain worsens on gabapentin is imagining it. But it does mean that reading about gabapentin’s side effects, hearing negative experiences from other patients, or being told by a doctor to “watch for worsening pain” can set up a self-fulfilling expectation. Pain perception is genuinely plastic, and negative expectations can amplify real sensations. For someone trying to evaluate whether gabapentin is actually helping or hurting, this adds a confounding layer that is difficult to untangle without structured dose adjustments and careful tracking.

Genetic Variation in Response

Not everyone’s body handles gabapentin the same way, and emerging research suggests genetics play a role. A genome-wide study investigating gabapentin efficacy in women with chronic pelvic pain noted that variation in response is thought to be partially driven by pharmacokinetic factors like the activity of drug transporters, age, and kidney function.¹⁴ This means two people taking the same dose might achieve very different blood levels and very different clinical outcomes, even if both have normal kidney function.

Pharmacogenomics in pain management is still in its early stages, and clinicians do not routinely test for genetic variants before prescribing gabapentin. In practice, this means the only way to know whether gabapentin will work for your particular nerve pain is to try it, titrate the dose carefully, and assess the results honestly over time. If the drug seems to be making things worse, that could reflect a genetic predisposition toward poor absorption, faster clearance, or a pain biology that simply does not respond to calcium channel modulation. It is a legitimate reason to move on to a different medication rather than pushing to higher and higher doses.